Navigation Links
Mindray to Attend the JPMorgan 4th Annual China Conference
Date:4/9/2008

SHENZHEN, China, April 9, 2008 /Xinhua-PRNewswire-FirstCall/ -- Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices in China with a rapidly growing international presence, today announced that Mr. Minghe Cheng, Mindray's executive vice president of strategic development and Ms. May Li, Mindray's investor relations manager, will attend the JPMorgan 4th Annual China Conference to be held at the Grand Hyatt Hotel in Beijing, China from Wednesday, April 23, 2008 to Friday, April 25, 2008.

Mr. Cheng and Ms. Li will hold one-on-one meetings with investors on Thursday, April 24, 2008 and Friday, April 25, 2008 to discuss Mindray's recent developments and 2008 domestic and international strategy.

About Mindray

Mindray Medical International Limited is a leading developer, manufacturer and marketer of medical devices in China with a significant and growing presence worldwide. Established in 1991, Mindray offers a broad range of products across three primary business segments: patient monitoring & life support products, in-vitro diagnostic products, and medical imaging systems. Mindray is headquartered in Shenzhen, China, and has 29 local sales and service offices in China, as well as sales and service offices in Amsterdam, Istanbul, London, Mexico City, Moscow, Mumbai, Sao Paulo, Seattle, Toronto and Vancouver. For more information, please visit http://www.mindray.com .

For investor inquiries please contact:

In China:

Susan Du

Mindray Medical International Limited

Tel: +86-755-2658-2518

Email: Susan.Du@Mindray.com

Jus
'/>"/>

SOURCE Mindray Medical International Limited
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Mindray Selects Actel Low-Power Flash FPGAs for Demanding Medical Equipment Applications
2. Mindray to Report Third Quarter 2007 Financial Results on November 1, 2007
3. Mindray to Attend 2007 RSNA Conference in Chicago
4. Mindray to Attend 2008 CLSA Asia Investors Forum
5. Mindray to Exhibit at 2008 European Congress of Radiology Annual Meeting
6. Mindray to Report Fourth Quarter and Fiscal Year 2007 Financial Results on March 5, 2008
7. Mindray Medical International Announces Full Year and Fourth Quarter 2007 Results
8. Mindray to Attend the 11th Credit Suisse Asian Investment Conference
9. Mindrays Laptop-size M5 and BS-200 Receive FDA Clearance
10. AdvaMed 2007 Exceeds Attendance Expectations With More Than 1,100 Participants from 35 States and 25 Countries
11. Couples attending counseling sessions together better prepared to ease childrens concerns
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... Healthcare Solutions , the parent ... today announced the appointment of Richard Leonardo to ... position, Leonardo will direct Healthcare Solutions’ national sales ... initiatives. , Recognized in the property and casualty ... more than 20 years of experience in business ...
(Date:6/18/2013)... New York, New York (PRWEB) June 18, 2013 ... forward in both state and federal court, a new report ... of more than 70,000 U.S. Food & Drug Administration (FDA) ... According to NewsChannel5 in Cleveland, Ohio, over 4.700 Mirena ... since 2008, while more than 1,300 have reportedly experienced uterine ...
(Date:6/18/2013)... By studying one of the most successful ... of successful strategies in his article What We Can ... Study. , The inspirational brand Gollan refers to is ... an impressive 62 million followers (and rising). , The ... Facebook Pages earlier this year. The Facebook data tracking publication ...
(Date:6/18/2013)... likely to keep their scheduled medical appointments and ... physician listens, explains things clearly and knows them as ... research suggests. , "If people feel their doctor really ... doctor has their best interests at heart and may ... leader Tabor E. Flickinger, M.D., M.P.H., a fellow in ...
(Date:6/18/2013)... research scientist Daniel Perlman has discovered a way to ... foods that are consumed by humans, potentially opening the ... A U.S. patent (#8,460,738) on the new process and ... Phytosterols in plants and cholesterol molecules in animals are ... are attracted to one another. When they mix in ...
Breaking Medicine News(10 mins):Health News:Healthcare Solutions Appoints Richard Leonardo to Chief Sales Officer 2Health News:Mirena Lawsuit News: Bernstein Liebhard LLP Comments on Mounting Reports of Mirena Side Effects, Including Device Migration, Uterine Perforations 2Health News:Mirena Lawsuit News: Bernstein Liebhard LLP Comments on Mounting Reports of Mirena Side Effects, Including Device Migration, Uterine Perforations 3Health News:Casey Gollan Shows What We Can Learn From One of the Best Facebook Pages There Is 2Health News:Casey Gollan Shows What We Can Learn From One of the Best Facebook Pages There Is 3Health News:Respect may be the key to stopping patient 'no shows' 2Health News:Brandeis scientist invents anti-cholesterol process 2
... to identifying high-risk behaviors among adolescents. Injury risk, ... leading causes of adolescent morbidity and mortality; yet pediatricians ... concerns. That paradox of care is the motivation behind ... Pediatrics, which found adolescents who participated in computerized screening ...
... adults and is emerging in the world of pediatrics. A ... D insufficiency, causes rickets in children and can be treated ... as increased sun exposure. , A new study ... the first study to investigate vitamin D insufficiency in pediatric ...
... 1 Aflac Incorporated,announced today that Martin A. Durant ... chief financial officer. Susan R. Blanck has been,promoted to ... are,effective June 1, 2008., Durant first joined Aflac ... He was with Aflac for 10 years, eventually serving ...
... Prenatal biochemical screening tests are widely used to look ... serious handicap, or even death during gestation or in the ... able to detect fewer than half of the total chromosomal ... conference of the European Society of Human Genetics tomorrow (Monday ...
... of particular gene respond well to targeted therapy , , ... who have the normal version of a particular gene ... that includes adding the targeted therapy Erbitux to chemotherapy. ... normal, or "wild-type" form of the gene, according to ...
... melanoma tumors may make the cancer more vulnerable to chemotherapy, ... Duke Comprehensive Cancer Center. , We tested a compound that ... on the surface of a melanoma cell," said Douglas Tyler, ... Medical Center, and senior investigator on this study. "When chemotherapy ...
Cached Medicine News:Health News:Waiting room gadget may prove to be a life-saver 2Health News:First study to examine vitamin D insufficiency in pediatric patients with low bone density 2Health News:Martin Durant Promoted to Executive Vice President and Deputy CFO; Sue Blanck Promoted to First Senior Vice President of Aflac Japan 2Health News:Martin Durant Promoted to Executive Vice President and Deputy CFO; Sue Blanck Promoted to First Senior Vice President of Aflac Japan 3Health News:Prenatal biochemical screening only detects half of chromosomal abnormalities 2Health News:Prenatal biochemical screening only detects half of chromosomal abnormalities 3Health News:Erbitux Works Well for Two-Thirds of Colon Cancer Patients 2Health News:Erbitux Works Well for Two-Thirds of Colon Cancer Patients 3Health News:Combination therapy packs 1-2 punch against melanoma 2
(Date:6/18/2013)... SYDNEY, Australia And EMERYVILLE, ... Adamas Pharmaceuticals, Inc. presented final results today from ... HCl extended release) capsules demonstrating a statistically significant ... change from baseline at week 8 versus placebo ... is Adamas, investigational extended-release formulation of amantadine intended ...
(Date:6/17/2013)... LOS ANGELES , June 17, 2013 ... TopProdeals.com , a technology platform that connects buyers ... evolved into being an industry leader. ... scenes at TopProdeals™ are intimately familiar with the dental ... the healthcare community and have diligently worked to negotiate ...
(Date:6/17/2013)... SAN DIEGO , June 17, 2013 BioMed ... that its board of directors has declared a second quarter ... dividend is equivalent to an annualized dividend of $0.94 per ... payable on July 15, 2013 to stockholders of record at ... About BioMed Realty Trust BioMed Realty delivers ...
Breaking Medicine Technology:Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 2Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 3Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 4Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 5Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 6TopProdeals.com Rises to Top as Discount Dental Supply Leader 2BioMed Realty Trust Declares Second Quarter 2013 Common Stock Dividend 2BioMed Realty Trust Declares Second Quarter 2013 Common Stock Dividend 3
... WOONSOCKET, R.I., Sept. 19 CVS/pharmacy today,announced that it ... vaccinations in over 4,000 of its stores across the ... on October 1, 2007 and continue,through November. For dates, ... option #1, or visit the CVS.com online Store,Finder to ...
... Targanta Therapeutics Corporation,today released detailed data ... of its lead antibiotic drug candidate, oritavancin, ... of susceptible and resistant strains of,gram- positive ... the 47th,Annual Interscience Conference on Antimicrobial Agents ...
Cached Medicine Technology:CVS/pharmacy Offers Flu Vaccinations in Over 4,000 Stores 2Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria 2Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria 3Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria 4Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria 5
Delicate Desmarres lid retractors, round serrated handle, very thin blades, polished finish, size 1....
2.0 mm cup , straight shaft, Flat handle, length 125.0 mm....
Size 4 - 2.25 mm...
The Storz Protege is an anterior segment unit only....
Medicine Products: